Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/sage/tofacitinib-for-the-treatment-of-refractory-palmoplantar-psoriasis-a-DwywuQbllh
References (13)
-
K. Papp, M. Menter, M. Abe, B. Elewski, S. Feldman, A. Gottlieb, R. Langley, T. Luger, D. Thaçi, M. Buonanno, P. Gupta, J. Proulx, S. Lan, R. Wolk, Opt investigators (2015)
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo‐controlled, phase III trialsBritish Journal of Dermatology, 173
-
D. Haynes, C. Topham, Erika Hagstrom, T. Greiling (2020)
Tofacitinib for the treatment of recalcitrant palmoplantar pustulosis: A case reportAustralasian Journal of Dermatology, 61
-
A. Berekméri, Farrouq Mahmood, M. Wittmann, P. Helliwell (2018)
Tofacitinib for the treatment of psoriasis and psoriatic arthritisExpert Review of Clinical Immunology, 14
-
W. Damsky, B. King (2017)
JAK inhibitors in dermatology: The promise of a new drug classJournal of the American Academy of Dermatology, 76
-
F. Tian, Zhaoyan Chen, Ting Xu (2019)
Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysisThe Journal of International Medical Research, 47
-
R. Mössner, P. Hoff, J. Mohr, D. Wilsmann-Theis (2020)
Successful therapy of palmoplantar pustulosis with tofacitinib—Report on three casesDermatologic Therapy, 33
-
(2009)
HIGHLIGHTS OF PRESCRIBING INFORMATION -
Food and drug administration -
V. Lernia, F. Bardazzi (2016)
Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasisDrug Design, Development and Therapy, 10
-
J. Hao (2014)
Targeting Interleukin-22 in PsoriasisInflammation, 37
-
I. Raposo, T. Torres (2016)
Palmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future ProspectsAmerican Journal of Clinical Dermatology, 17
-
Adam Pettey, R. Balkrishnan, S. Rapp, A. Fleischer, S. Feldman (2003)
Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice.Journal of the American Academy of Dermatology, 49 2
-
E. Farley, S. Masrour, J. Mckey, A. Menter (2009)
Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool.Journal of the American Academy of Dermatology, 60 6
- Publisher
- SAGE
- Copyright
- © The Author(s) 2021
- ISSN
- 2475-5303
- eISSN
- 2475-5311
- DOI
- 10.1177/2475530321995516
- Publisher site
- See Article on Publisher Site
Abstract
Background:Palmoplantar psoriasis can severely impact patient quality of life. Despite the influx of many new medications, it remains one of the most challenging psoriasis phenotypes to treat.Case Description:Herein, we present a case series of 7 patients with hyperkeratotic palmoplantar psoriasis refractory to systemic therapy who were successfully treated with tofacitinib, a Janus kinase (JAK) 1/3 inhibitor.Conclusions:Tofacitinib may be an effective therapy for the management of recalcitrant palmoplantar psoriasis. The efficacy of tofacitinib for the treatment of palmoplantar psoriasis might clarify the dependence on this subtype of psoriasis on specific cytokines that signal through JAK 1/3.
Journal
Journal of Psoriasis and Psoriatic Arthritis – SAGE
Published: Apr 1, 2021
Keywords: psoriasis; palmoplantar psoriasis; tofacitinib; Janus Kinase inhibitors